New schizophrenia drug shows promise in large trial
NCT ID NCT01625000
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This study tested a new drug called MP-214 in 512 people with schizophrenia who were having a flare-up of symptoms. The goal was to see if the drug reduces symptoms like hallucinations and delusions better than a placebo. Researchers measured symptom changes using standard rating scales over 6 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Sapporo, Hokkaido, Japan
-
Study site
Seoul, South Korea
-
Study site
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.